Recent studies have revealed that endothelins (ETs) have at least two types of receptors. One receptor has high affinity to ET-1 and ET-2 and low affinity to ET-3 (A type). The other receptor binds almost equally to ET-1, ET-2, and ET-3 (B type). In this study, microlocalization of mRNA coding for the A-type and B-type ET receptors was carried out in the rat kidney using a reverse transcription and polymerase chain reaction assay of individual microdissected renal tubule segments along the nephron, glomeruli, vasa recta bundle, and arcuate arteries. Large signals for the B-type receptor polymerase chain reaction product were detected in the initial and terminal inner medullary collecting duct and the glomerulus, while small signals were found in the cortical collecting duct and outer medullary collecting duct, vasa recta bundle, and arcuate artery. In contrast, A-type receptor mRNA was detected only in the glomerulus, vasa recta bundle, and arcuate artery. Thus, the two ET receptor subtypes are distributed differently along the nephron. This suggests that the two types of receptors and ET families may affect kidney functioning in different ways.
Introduction
Endothelin-1 (ET-1),' initially described as a 21-amino acid vasoactive peptide secreted by cultured vascular endothelial cells (1) , is now known to be a family ofthree distinct peptides (2) . ET-1 differs in structure from ET-2 and ET-3 by two and six amino acid residues, respectively (2) . Recently, two distinct ET receptors (ET-Rs) were described (3) (4) (5) , each belonging to Receivedfor publication 4 October 1991 and in revisedform 9 January 1992.
1. Abbreviations used in this paper: CCD, cortical collecting duct; ET, endothelin; ET-R, ET receptor; Glm, glomeruli; GAPDH, glyceraldehyde-3-phosphate-dehydrogenase; IMCD, inner medullary collecting duct; similarly, iIMCD and tIMCD, initial and terminal parts, respectively, of the IMCD; OMCD, outer medullary collecting duct; PCR, polymerase chain reaction, RT, reverse transcription. the superfamily of rhodopsin-like receptors, with seven transmembrane domains. One receptor (A-type ET-R) binds ET-I with 2-to 10-fold higher affinity than ET-2 and with > 100-fold higher affinity than ET-3 (3, 5) . The other receptor (B-type ET-R) has similar affinities for all three peptides (4) .
Many reports have been studied the renal action of ET-1. GFR and renal blood flow decrease and urinary flow rate increases after administration of ET-1 (6) . ET-I has also been reported to influence the function of the glomerulus (7) and inner medullary collecting duct (8, 9) . Autoradiographic study revealed that the binding sites of ET-I were mainly the glomerulus, vascular system, and renal medulla (10, 1 1). However, the receptor subtypes are not clear in the binding study. The presence of ET-R in the kidney has been confirmed by Northern blot analysis, which revealed that B-type ET-R mRNA was expressed in rat (4) and human kidney (12) . A-type ET-R mRNA is also present in low amounts in rat (5) and bovine kidney (3) . Because of the heterogeneity of the kidney, the Northern blot data did not give information about which parts of the nephron segments or renal structure have these receptor mRNAs. It seems very important to know the precise localization of both types of receptor expression along the nephron segments and renal vascular system in order to understand the renal actions of ETs.
Recently, Moriyama et al. (13) (14) .
In the present study, we employed the RT-PCR technique for the precise localization of A-type and B-type ET-R mRNA in microdissected renal tubules, glomeruli (Glm), arcuate arteries, and vasa recta bundles.
Methods
Renal tubule microdissection. Male Sprague-Dawley rats weighing 75-100 g were killed by decapitation. The aorta was cannulated with polyethylene tubing below the left kidney, and the left kidney was perfused in vivo. The kidney was perfused initially with 10 ml ofice-cold dissection solution (solution 1) and then with 10 ml of the same solution containing 1 mg/ml collagenase (collagenase solution) (type I, 300 U/ mg, Sigma Chemical Co., St. Louis, MO) and 1 mg/ml BSA (Sigma Chemical Co.). The dissection solution (solution 1) contained the following (mM): 135 NaCI, 1 Na2SO4, 1.2 MgSO4, 5 KC1, 2 CaCl2, 5.5 glucose, and 5 Hepes (pH 7.4).
The left kidney was removed and a coronal section was made that contained the entire corticopapillary axis. This section was cut into four pieces: cortex, outer medulla, the outer 25% ofinner medulla, and the inner 75% of inner medulla. These pieces were transferred into individual tubes containing 1 ml of the same collagenase solution that was used to perfuse the kidney. The tubes were incubated for 30 min (cortex and outer medulla) or 40 min (inner medulla) at 370C in a shaking water bath. The solutions were bubbled with 100% oxygen during these incubations. Then tissues were transferred to the dissection solution containing 10 mM vanadyl ribonucleotide complex (Life Technologies Inc., Grand Island, NY), a potent ribonuclease (RNase) inhibitor, and they were placed on ice until microdissection.
Following previously described techniques ( 14), we microdissected the following structures: Glm, proximal convoluted tubule (PCT), cortical collecting ducts (CCD), arcuate artery, outer medullary collecting duct (OMCD), outer medullary thick ascending limb (MTAL), outer medullary vasa recta bundle, the initial part ofinner medullary collecting duct (iIMCD), and the terminal part of inner medullary collecting duct (tIMCD). In the dissection ofglomeruli, care was taken to remove all attached pieces of tubule, as well as afferent and efferent arterioles. PCT and CCD segments were obtained from medullary rays in cortical slices. The arcuate arteries were dissected from the junction of cortex and outer stripe of the outer medulla. MTAL, OMCD, and vasa recta were dissected from the inner stripe of outer medulla. The IMCD segments were dissected from the outer 25% of inner medulla (iIMCD) and the inner 75% of inner medulla (tIMCD).
The lengths of the dissected tubules were measured using a calibrated eyepiece micrometer. Generally, 2-mm lengths of the renal tubule segments or arcuate arteries were transferred to each assay tube, as indicated. Because it was impossible to separate individual vasa recta in a microdissected vascular bundle, we transferred entire bundles into the assay tubes for the RT-PCR procedure.
Microdissected structures were transferred to a separate wash-dish using a bent, polished, Pasteur pipette coated with 0.1% BSA (RNasefree, Boehringer Mannheim, GmBH, Mannheim, FRG). This washdish contained 10 (14) . Prehybridization/hybridization washes were also the same as previously described (14) .
To confirm that the PCR products were really A-type and B-type ET-R cDNAs, the PCR products were sequenced. PCR products from Glm were separated by gel electrophoresis. PCR products of A-type and B-type ET-R were subcloned into pGEM-3Zf(-) vector (Promega Boitec, Madison, WI), then sequenced using the dideoxynucleotide chain-termination reaction of Sanger et al. (18) .
Relative-quantitation of mRNA levels from autoradiographs. The PCR products of B-type ET-R were detectable from several nephron segments. The relative amount of PCR products was determined by densitometer scanning of autoradiographs using a laser densitometer (Hoeler Scientific Instruments, San Francisco, CA). Each RT-PCR experiment included one or more tIMCD samples. For relative quantitation, we used the densitometry value from the tIMCD samples as an internal standard (100%) and calculated the percentage of the tIMCD value for each segment.
To test the relationship between the quantity of starting material and that of amplification product as reflected by densitometry values, we compared amplification products from one, three, and five Glm.
Statistics. The results were given as mean ±SEM. The differences were tested using analysis of variance. P < 0.05 was considered significant. Relationship between the quantity ofstarting material and that ofamplification product (Fig. 1) . We compared amplification products from one, three, and five Glm. A typical gel is shown in the upper portion ofFig. 1. Assigning the five-Glm sample as an arbitrary unit of 100, the values obtained were (mean±SEM, n = 5) 25.5±4.8 (one glomerulus) and 68.9±5.7 (three Glm). Linear regression analysis showed a high correlation between densitometry values and the numbers ofGlm (r = 0.99). Distribution ofA-type ET-R mRNA in microdissected structures (Fig. 2) . Each reaction was performed using either 2 mm of tubule length, 5 Glm, a single vasa recta bundle, or a 2-mm length of arcuate artery. A single band of predicted size (787 bp) was consistently found from the Glm, vasa recta, and arcuate artery (Fig. 2 A) . The Southern blots of the gels demonstrated specific binding ofthe oligonucleotide probe to the 787-bp product (Fig. 2 B) . We confirmed that the PCR product has identical sequence to A-type ET-R cDNA by sequencing the subcloned PCR product. When the PCR procedure was carried out in the absence ofreverse transcriptase, the 787-bp band was not seen and there was no other recognizable band. This indicated that the 787-bp band originated from mRNA, not from genomic DNA, which was presumably digested by DNase treatment. No band for A-type ET-R was detectable from any tubule segments. Therefore, we did not do relative-quantitative analysis of the PCR products for A-type ET-R. The amplifica-B C *_ .am.k.
-309 bp (Fig. 2 C) .
Distribution ofB-typeET-R mRNA in microdissectedstructures (Fig. 3) . A single band was consistently found from the Glm, iIMCD, tIMCD, OMCD, CCD, MTAL, and vasa recta for B-type ET-R (Fig. 3 A) . This band was the predicted size (919 bp). The Southern blots ofthe gels demonstrated specific binding of the oligonucleotide probe to the 919-bp product (Fig. 3 B) . We confirmed that the PCR product has identical sequence to B-type ET-R cDNA by sequencing the subcloned PCR product. When the PCR procedure was carried out in the absence of reverse transcriptase, the 91 9-bp band was not seen and there was no other recognizable band. Among renal tubule segments, the largest signal was consistently found in tIMCD. Furthermore, a large signal was consistently seen in iIMCD, and Glm. CCD and OMCD also showed pronounced bands. The arrow indicates expected PCR products size (670 bi Small but detectable bands were observed from MTAL, vasa recta bundle, and arcuate artery (not shown in Fig. 3 ). The amplification product of GAPDH was detected from all renal structures at predicted size (309 bp) and served as a positive control for the RT-PCR reaction (Fig. 3 C) Relative levels of the B-type ET-R amplification products among the nephron segments (Fig. 4) . The densitometer values are presented as percentages of the tIMCD value measured in (6) . ET increases renal vascular resistance and contracts glomerular mesangial cells. These reports suggest that ET may influence glomerular function (7) . Our results show that the glomerulus has both types of ET-R mRNA. The functional difference between A-type and B-type ET-R is not known, but the glomerular actions of ET may be the result of both A-type and B-type receptor functions. Another work indicated that ET decreased urinary sodium excretion, urine osmolality, and osmolar clearance, and increased free water clearance (19) . Recently, we reported that ET specifically inhibited vasopressin-dependent cAMP accumulation in CCD, OMCD, and IMCD (20) . Zeidel et al. (9) reported that ET inhibited LU ti ,r Na-K-ATPase activity in IMCD cells. These reports suggest that ET has physiological roles in the distal nephron segments. We also reported that ET inhibited fluid absorption in rat CCD (20) and also inhibited arginine-vasopressin-stimulated osmotic water permeability in rat tIMCD (21) . From our results, PCR signal for B-type ET-R was abundant in these segments, especially in initial and terminal IMCD, although we were not able to detect A-type ET-R signal from these segments. It seems likely that the ET has effects on the distal segments through B-type ET-R, but not A-type ET-R.
Many papers have reported on the renal binding sites of radiolabeled ET. Koseki et al. (10) found a high density of ET binding sites in the arcuate artery, vascular bundle, glomerulus, and papilla. Kohzuki et al. ( 11) reported similar results, showing that ET binding sites were present in the glomerulus, vascular system, and medulla. These binding studies used only radiolabeled ET-1, so these results could not distinguish between A-type and B-type ET-R. Although all ofthese reports demonstrated binding sites in renal papilla, it seemed difficult to determine whether the signals were from medullary collecting tubules or vasa recta. The advantage of our method is that we were clearly able to distinguish A-type and B-type ET-R because we selected specific primers for each receptor. In addition, we used microdissected identified structures, so it was relatively clear to determine which segments had signals. From our results, we can speculate the results of previous reports as follows: the bindings to the glomerulus are a combination of A-type and B-type ET-R, those to the vascular system represent mainly A-type ET-R, and those to the medulla are a combination of two signals, namely, B-type ET-R of medullary renal tubules and A-type ET-R of the vasa recta bundle.
The functional difference between A-type and B-type ET-R has not been well studied. ETs may elicit biological responses by various signal transduction mechanisms, including G protein-coupled activation of phospholipase C and phosphatidylinositol hydrolysis, and increasing cytosolic Ca2+ concentration in target cells (22) . The possibility of another transduction system was also reported. ETs cause not only vasoconstriction, but also transient vasodilation, which may be evoked partly through the production ofendothelium-derived relaxing factor (2, 23) . Recently, Emori et al. (24) reported that ET-3 stimulates production of endothelium-derived nitric oxide in cultured bovine endothelial cells.
To understand the functional difference between A-type and B-type receptors, it is important to know the organ-specific mRNA expressions of each receptor. The mRNA for A-type and B-type ET-R shows different tissue distribution. B-type ET-R is widely expressed in brain, placenta, kidney, and a small amount in aorta (12) but is undetectable in a vascular smooth muscle cell line (A-10 cell) (4) . By contrast, A-type ET-R mRNA is detected in heart, lung, brain, kidney, and aorta but is not expressed in endothelial cells (25) . These reports suggest that the B-type ET-R is expressed in vascular endothelial cells, where it possibly mediates the release ofendothelial-derived relaxing factor and prostacyclin (1, 12, 26) . ET has also been reported to stimulate prostaglandin E2 and inhibit Na-K-ATPase activity (9) . Our data showed that renal tubules express only B-type ET-R. Therefore, the renal tubular actions of ET may be mediated through endothelial-derived relaxing factor and prostacyclin, besides increasing cytosolic Ca2+ concentration.
Our approach to relative quantitation of the B-type ET-R PCR amplification product was to run Southern blots of the amplified cDNA using a 32P-labeled hybridization probe and then to assess the amount ofbound radioactivity by densitometry of the resulting autoradiograms. The 
